Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Abbott Laboratories is a dividend growth machine that's known for consistency. AbbVie's dividend has more than quadrupled ...

Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. ... The growth in its new GLP-1 drugs has transformed the business in a strong, ...

Three stocks with yields that are less than 2% but that have been increasing their dividends at high rates in recent years ...

Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. A couple of key events are on the horizon this month during which the company will release ...